We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

MERIDIAN BIOSCIENCE

Meridian Bioscience manufactures, markets, and distributes diagnostic test kits, purified reagents and biopharmaceuti... read more Featured Products: More products

Download Mobile App





Meridian Bioscience Launches New Animal-Free Immunoassay Interference Blockers

By LabMedica International staff writers
Posted on 26 Jul 2023
Print article
Image: The new K-Block and Mouse-Free IgG overcome challenges encountered with traditional animal-based blockers (Photo courtesy of Meridian)
Image: The new K-Block and Mouse-Free IgG overcome challenges encountered with traditional animal-based blockers (Photo courtesy of Meridian)

Meridian Bioscience Inc. (Cincinnati, OH, USA) is spotlighting its newly-introduced animal-free immunoassay interference blockers at this year's AACC conference. Immunoassay interference can lead to false positives and negatives, resulting in incorrect interpretation and faulty patient diagnosis. Interference primarily stems from Human Anti-Mouse Antibodies (HAMA), Rheumatoid Factor (RF), and Heterophilic Antibodies (HA). HAMA, detected in up to 25% of patients, combined with HA, constitute the major factors contributing to false positives in immunoassays. Including blockers in every immunoassay is essential to avoid such interference. Traditionally, animal-based interference blockers have been employed to enhance assay accuracy; however, these are prone to cross-reactivity with assay reagents, lot-to-lot variability, and supply shortages, as evidenced during the COVID-19 pandemic.

Meridian's Life Science division has unveiled two new animal-free immunoassay interference blockers, K-Block, and Mouse-Free IgG, offering a potential solution to these issues. These innovative blockers are completely animal-free and provide comparable or superior performance than traditional animal-derived blockers. Meridian's new K-Block and Mouse-Free IgG overcome the obstacles associated with conventional animal-based blockers. These advanced blockers enhance assay specificity, reduce lot-to-lot variability, comply with sustainability considerations, and minimize contamination risks from animal-derived components. Preliminary testing in ELISA-based assays has revealed a strong performance of K-Block and Mouse-FREE IgG compared to other commercial animal-derived blockers.

The introduction of these products is in line with Meridian's objective to pioneer sustainable and innovative raw materials for diagnostic assay manufacturers. By adopting these animal-free products, manufacturers can contribute to reducing their environmental footprint by optimizing energy and resource consumption and maintaining compliance with emerging regulatory standards. Meridian continues to champion environmental responsibility within the industry and is showcasing the two new animal-free immunoassay interference blockers, K-Block, and Mouse-Free IgG, at AACC 2023.

“At Meridian, we are deeply committed to supporting our customers who are seeking non-animal-derived raw materials in diagnostic assays,” said Lourdes Weltzien, Ph.D., President - Life Science, Meridian Bioscience. “Our novel 100% animal-free blockers deliver on this commitment while avoiding the need to consume millions of mice each year in the process. This innovative method not only allows us to scale up quickly but also delivers results that are equivalent or even superior in quality. With this new product line, we reaffirm our dedication to environmental sustainability and social responsibility, ensuring a more ethical and responsible approach in our operations as well as our customers.”

Related Links:
Meridian Bioscience Inc. 

Gold Member
Hematology Analyzer
Swelab Lumi
New
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Multiparametric Control
B·R·A·H·M·S GM KRYPTOR QC
New
Chemiluminescence Immunoassay Analyzer
AutoLumo A6200/A6600

Print article

Channels

Molecular Diagnostics

view channel
Image: Three newly identified protein biomarkers have the potential to improve diagnostic tools for colorectal cancer (Photo courtesy of Adobe Stock)

New Protein Biomarkers to Improve Diagnostic Tools for Colorectal Cancer

Colorectal cancer is a leading cause of cancer-related deaths globally, and its incidence is expected to rise in the coming decades. This cancer begins when abnormal cells grow uncontrollably in the large... Read more

Microbiology

view channel
Image: The CRISPR-TB Blood Test provides accurate, rapid, and cost-effective diagnosis (Photo courtesy of 123RF)

CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening

Tuberculosis (TB) continues to be a leading cause of global mortality, with 10.6 million new cases and 1.6 million deaths annually. Diagnosing TB remains difficult, with smear microscopy offering only... Read more

Pathology

view channel
Image: The AI tool can search through data and histology images for much more precise information on cancer treatment effectiveness (Photo courtesy of Shutterstock)

AI Tool Analyzes 30K Data Points Per Medical Imaging Pixel in Cancer Search

A new artificial intelligence (AI)-powered tool can detect cell-level characteristics of cancer by analyzing data from very small tissue samples, some as tiny as 400 square micrometers, equivalent to the... Read more

Industry

view channel
Image: The game-changing immunoassay diagnostics platform delivers results from whole blood sample in 10 minutes (Photo courtesy of SpinChip)

bioMérieux Acquires Norwegian Immunoassay Start-Up SpinChip Diagnostics

bioMérieux (Marcy l’Étoile, France) has agreed to acquire SpinChip Diagnostics (Oslo, Norway), the developer of a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.